Brivaracetam, a selective high-affinity synaptic vesicle protein 2A (SV2A) ligand with preclinical evidence of high brain permeability and fast onset of action

Epilepsia

Volumn 57, Issue 2, 2016, Pages 201-209

  Nicolas, Jean Marie ^a   Hannestad, Jonas ^a   Holden, Daniel ^b   Kervyn, Sophie ^a   Nabulsi, Nabeel ^b   Tytgat, Dominique ^a,c   Huang, Yiyun ^b   Chanteux, Hugues ^a   Staelens, Ludovicus ^a   Matagne, Alain ^a   Mathy, François Xavier ^a   Mercier, Joël ^a   Stockis, Armel ^a   Carson, Richard E ^b   Klitgaard, Henrik ^a  

^a UCB PHARMA   (Belgium)

^b YALE UNIVERSITY SCHOOL OF MEDICINE   (United States)

^c SANOFI AVENTIS DEUTSCHLAND GMBH   (Germany)

Author keywords

Blood brain barrier; Brivaracetam; Levetiracetam; Onset of action; Physiologically based pharmacokinetic; Status epilepticus

Indexed keywords

BRIVARACETAM; CARBON 14; ETIRACETAM; LEVETIRACETAM C 14; PROTEIN; SYNAPSE VESICLE PROTEIN 2A; TRACER; UNCLASSIFIED DRUG; 2 PYRROLIDONE DERIVATIVE; 2-(2-OXO-4-PROPYLPYRROLIDIN-1-YL)BUTANAMIDE; ANTICONVULSIVE AGENT; MEMBRANE PROTEIN; NERVE PROTEIN; PIRACETAM; SV2A PROTEIN, HUMAN;

ADULT; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTICONVULSANT ACTIVITY; ARTICLE; AUDIOGENIC SEIZURE; BEAGLE; BLOOD BRAIN BARRIER; CACO 2 CELL LINE; CELL MEMBRANE PERMEABILITY; CLONIC SEIZURE; CONTROLLED STUDY; DRUG BLOOD LEVEL; DRUG BRAIN LEVEL; DRUG CEREBROSPINAL FLUID LEVEL; DRUG MECHANISM; HUMAN; HUMAN CELL; IN VITRO STUDY; MALE; MEMBRANE PERMEABILITY; NONHUMAN; POSITRON EMISSION TOMOGRAPHY; PREDICTION; PRIORITY JOURNAL; RAT; RHESUS MONKEY; SINGLE DRUG DOSE; SURFACE AREA; ANALOGS AND DERIVATIVES; ANIMAL; BRAIN; COMPARATIVE STUDY; DOG; METABOLISM; MOLECULARLY TARGETED THERAPY; MOUSE; PERMEABILITY; REFLEX EPILEPSY; SCINTISCANNING;

ANIMALS; ANTICONVULSANTS; BLOOD-BRAIN BARRIER; BRAIN; CACO-2 CELLS; DOGS; EPILEPSY, REFLEX; HUMANS; IN VITRO TECHNIQUES; MACACA MULATTA; MEMBRANE GLYCOPROTEINS; MICE; MOLECULAR TARGETED THERAPY; NERVE TISSUE PROTEINS; PERMEABILITY; PIRACETAM; POSITRON-EMISSION TOMOGRAPHY; PYRROLIDINONES; RATS;

EID: 84959478089     PISSN: 00139580     EISSN: 15281167     Source Type: Journal    
DOI: 10.1111/epi.13267     Document Type: Article

References (37)

1. Varelas PN, Spanaki MV, Mirski MA,. Status epilepticus: an update. Curr Neurol Neurosci Rep 2013; 13: 357.
2. Al-Mufti F, Claassen J,. Neurocritical care: status epilepticus review. Crit Care Clin 2014; 30: 751-764.
3. Ziai WC, Kaplan PW,. Seizures and status epilepticus in the intensive care unit. Semin Neurol 2008; 28: 668-681.
4. Wasterlain CG, Fujikawa DG, Penix L, et al., Pathophysiological mechanisms of brain damage from status epilepticus. Epilepsia 1993; 34 (Suppl 1): S37-S53.
5. Hesdorffer DC, Logroscino G, Cascino G, et al., Risk of unprovoked seizure after acute symptomatic seizure: effect of status epilepticus. Ann Neurol 1998; 44: 908-912.
6. Kanner AM,. Epilepsy: psychiatric comorbidities and premature death in epilepsy. Nat Rev Neurol 2013; 9: 606-608.
7. Brophy GM, Bell R, Claassen J, et al., Guidelines for the evaluation and management of status epilepticus. Neurocrit Care 2012; 17: 3-23.
8. Riviello JJ Jr, Claassen J, LaRoche SM, et al., Treatment of status epilepticus: an international survey of experts. Neurocrit Care 2013; 18: 193-200.
9. Rossetti AO,. Treatment options in the management of status epilepticus. Curr Treat Options Neurol 2010; 12: 100-112.
10. Silbergleit R, Durkalski V, Lowenstein D, et al., Intramuscular versus intravenous therapy for prehospital status epilepticus. N Engl J Med 2012; 366: 591-600.
11. Zelano J, Kumlien E,. Levetiracetam as alternative stage two antiepileptic drug in status epilepticus: a systematic review. Seizure 2012; 21: 233-236.
12. Treiman DM, Meyers PD, Walton NY, et al., A comparison of four treatments for generalized convulsive status epilepticus. Veterans Affairs Status Epilepticus Cooperative Study Group. N Engl J Med 1998; 339: 792-798.
13. Mula M,. Brivaracetam for the treatment of epilepsy in adults. Expert Rev Neurother 2014; 14: 361-365.
14. Matagne A, Margineanu DG, Kenda B, et al., Anti-convulsive and anti-epileptic properties of brivaracetam (ucb 34714), a high-affinity ligand for the synaptic vesicle protein, SV2A. Br J Pharmacol 2008; 154: 1662-1671.
15. Klein P, Schiemann J, Sperling M, et al., A randomized, double-blind, placebo-controlled, multicenter, parallel-group study to evaluate the efficacy and safety of brivaracetam in adult patients with partial onset seizures. Epilepsy Curr 2015; 15: 379. Abstract.
16. Rolan P, Sargentini-Maier ML, Pigeolet E, et al., The pharmacokinetics, CNS pharmacodynamics and adverse event profile of brivaracetam after multiple increasing oral doses in healthy men. Br J Clin Pharmacol 2008; 66: 71-75.
17. Sargentini-Maier ML, Espie P, Coquette A, et al., Pharmacokinetics and metabolism of 14C-brivaracetam, a novel SV2A ligand, in healthy subjects. Drug Metab Dispos 2008; 36: 36-45.
18. Chanteux H, Kervyn S, Gerin B, et al., (2015) In vitro pharmacokinetic profile of brivaracetam (BRV) reveals low risk of drug-drug interaction (DDI) and unrestricted brain permeability. Neurology 84: P4.276. Abstract.
19. 11C]UCB-J: a novel PET tracer for imaging the synaptic vesicle glycoprotein 2A (SV2A). J Nucl Med 2014; 55 (Suppl. 1): 355.
20. Shapiro JS, Stiteler M, Wu G, et al., Cisterna magna cannulated repeated CSF sampling rat model-effects of a gamma-secretase inhibitor on Abeta levels. J Neurosci Methods 2012; 205: 36-44.
21. Benedetti MS, Coupez R, Whomsley R, et al., Comparative pharmacokinetics and metabolism of levetiracetam, a new anti-epileptic agent, in mouse, rat, rabbit and dog. Xenobiotica 2004; 34: 281-300.
22. Liu X, Smith BJ, Chen C, et al., Use of a physiologically based pharmacokinetic model to study the time to reach brain equilibrium: an experimental analysis of the role of blood-brain barrier permeability, plasma protein binding, and brain tissue binding. J Pharmacol Exp Ther 2005; 313: 1254-1262.
23. Nicolas JM,. Species differences and impact of disease state on BBB. In, Di L, Kerns E H, (Eds) Blood-brain barrier in drug discovery: optimizing brain exposure of CNS drugs and minimizing brain side effects for peripheral drugs. Hoboken, NJ: Wiley & Sons Ltd, 2015: 66-93.
24. Hulhoven R, Scheen A, Watanabe S, et al., Bioavailability and safety of the intravenous administration of brivaracetam. Epilepsia 2008; 49 (Suppl. 7): 438.
25. Snoeck E, Jacqmin P, Sargentini-Maier ML, et al., Modeling and simulation of intravenous levetiracetam pharmacokinetic profiles in children to evaluate dose adaptation rules. Epilepsy Res 2007; 76: 140-147.
26. Yazdanian M, Glynn SL, Wright JL, et al., Correlating partitioning and caco-2 cell permeability of structurally diverse small molecular weight compounds. Pharm Res 1998; 15: 1490-1494.
27. Paixao P, Gouveia LF, Morais JA,. Prediction of the in vitro permeability determined in Caco-2 cells by using artificial neural networks. Eur J Pharm Sci 2010; 41: 107-117.
28. van de Waterbeemd H, Camenisch G, Folkers G, et al., Estimation of blood-brain barrier crossing of drugs using molecular size and shape, and H-bonding descriptors. J Drug Target 1998; 6: 151-165.
29. French J, Arrigo C,. Rapid onset of action of levetiracetam in refractory epilepsy patients. Epilepsia 2005; 46: 324-326.
30. Paulson OB, Gyory A, Hertz MM,. Blood-brain barrier transfer and cerebral uptake of antiepileptic drugs. Clin Pharmacol Ther 1982; 32: 466-477.
31. Doheny HC, Ratnaraj N, Whittington MA, et al., Blood and cerebrospinal fluid pharmacokinetics of the novel anticonvulsant levetiracetam (ucb L059) in the rat. Epilepsy Res 1999; 34: 161-168.
32. Tong X, Patsalos PN,. A microdialysis study of the novel antiepileptic drug levetiracetam: extracellular pharmacokinetics and effect on taurine in rat brain. Br J Pharmacol 2001; 133: 867-874.
33. Kaplan SA, Jack ML, Alexander K, et al., Pharmacokinetic profile of diazepam in man following single intravenous and oral and chronic oral administrations. J Pharm Sci 1973; 62: 1789-1796.
34. Bell DM, Richards G, Dhillon S, et al., A comparative pharmacokinetic study of intravenous and intramuscular midazolam in patients with epilepsy. Epilepsy Res 1991; 10: 183-190.
35. Greenblatt DJ, Shader RI, Franke K, et al., Pharmacokinetics and bioavailability of intravenous, intramuscular, and oral lorazepam in humans. J Pharm Sci 1979; 68: 57-63.
36. Wasterlain CG, Suchomelova L, Matagne A, et al., Brivaracetam is a potent anticonvulsant in experimental status epilepticus. Epilepsia 2005; 46 (Suppl. 8): 219.
37. Abraham MH,. The permeation of neutral molecules, ions, and ionic species through membranes: brain permeation as an example. J Pharm Sci 2011; 100: 1690-1701.